Stock Chart

BLRX

$2.37 +0.85%
Score: 51.0 HOLD
Pro
Screener
Vol: 0.21x (vs SPY: 0.2x | vs QQQ: 0.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Falling Wedge Bullish scenario quality 61/100
Measured-move target $2.38 (+0.4%) · apex ~31 bars ahead
Historically breaks up 63% of the time; target hit in 75% of up-breaks (n=385)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About BLRX - BioLineRX Ltd

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Key Statistics

Market Cap $12M

This BLRX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track BLRX's price movements with trendlines, gamma walls, and key support/resistance levels.